NCT02987504View on ClinicalTrials.gov

Study of Samalizumab in Patients With Advanced Cancer

PHASE1TerminatedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

November 17, 2016

Primary Completion Date

September 12, 2017

Study Completion Date

September 27, 2017

Conditions
Advanced Solid Tumors
Interventions
DRUG

Samalizumab

Samalizumab is a humanized, anti CD200 monoclonal antibody provided as a sterile 5 mg/milliliters (mL) solution for IV administration.

Trial Locations (3)

49503

Grand Rapids

78229

San Antonio

06510

New Haven

Sponsors
All Listed Sponsors
collaborator

Quintiles, Inc.

INDUSTRY

lead

Alexion Pharmaceuticals, Inc.

INDUSTRY